test tubes and beakers

Through the first quarter of 2024, venture investment has remained strong for biopharma and medtech companies.

The total amount of capital invested in biopharma therapeutics and discovery platforms increased approximately 33% compared to last quarter. Similarly, the total amount of deal value observed for medtech startups is nearly one-third of the total deal value for full-year 2023.

Additionally, despite challenges facing the broader exit environment, there was an uptick in the number of biopharma and medtech IPOs through the first quarter of the year.

J.P. Morgan’s biopharma therapeutics and medtech licensing reports explore the movement in each sector, offering insight on industry and investment trends that defined 2023 and will shed light onto the remainder of 2024. The reports, powered by DealForma, highlight:

  • Deal values in biopharma licensing partnerships
  • Trends in deal values for medical devices, diagnostics, digital health therapies and research tools
  • Venture investment amounts in therapeutic and platform companies
  • Investment and dealmaking on advanced therapies
  • IPO and M&A activity in each sector

Download the full reports to better understand these dealmaking trends.


Kathryn McDonough

Head of Life Sciences, Innovation Economy, Commercial Banking, J.P. Morgan

Skip Kelly

Head of Healthcare VC Coverage, Commercial Banking, J.P. Morgan